The estimated Net Worth of Global Strategic Fund, L.P.... is at least $525 Thousand dollars as of 1 April 2019. Global P owns over 50,000 units of Precision BioSciences stock worth over $525,000 and over the last 6 years Global sold DTIL stock worth over $0.
Global has made over 1 trades of the Precision BioSciences stock since 2019, according to the Form 4 filled with the SEC. Most recently Global bought 50,000 units of DTIL stock worth $800,000 on 1 April 2019.
The largest trade Global's ever made was buying 50,000 units of Precision BioSciences stock on 1 April 2019 worth over $800,000. On average, Global trades about 50,000 units every 0 days since 2019. As of 1 April 2019 Global still owns at least 50,000 units of Precision BioSciences stock.
You can see the complete history of Global P stock trades at the bottom of the page.
Over the last 6 years, insiders at Precision BioSciences have traded over $352,500 worth of Precision BioSciences stock and bought 224,670 units worth $1,909,002 . The most active insiders traders include Raymond F Schinazi, Llc Fmr, and Michael Amoroso. On average, Precision BioSciences executives and independent directors trade stock every 22 days with the average trade being worth of $357,735. The most recent stock trade was executed by Dario Scimeca on 7 June 2024, trading 301 units of DTIL stock currently worth $3,161.
Precision BioSciences, Inc., a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Precision BioSciences executives and other stock owners filed with the SEC include: